Foldax Tria LifePolymer Heart Valve Technology Honored with The Best Innovation Award at CRT 2020

The presentation, titled “Foldax Tria First in Human Implant of a Totally Synthetic Polymeric Aortic Heart Valve,” was given by Dr. Steven Yakubov, Chair of Advanced Structural Heart Disease at OhioHealth Riverside Methodist during the Best Innovation Competition session. The Tria heart valve with its LifePolymer technology was competing as one of the Top Ten Innovations at the 2020 CRT meeting.

“I am honored that the judges selected the Tria synthetic polymer heart valve presentation as the Best Innovation Award winner since all of the technologies presented were excellent examples of the extraordinary research being done in cardiovascular medicine today. The Foldax technology holds the promise of the next major advancement in heart valves after transcatheter delivery,” stated Dr. Yakubov.

Tria LifePolymer heart valves are made with LifePolymer, a novel, patented biopolymer developed specifically for heart valve application. By utilizing computer engineering and robotic manufacturing, Tria heart valves are designed to provide optimal durability and hemodynamics with exceptional value compared to current valves.

“This award provides continued validation of our goal to transform heart valve therapy. Our thanks go to Dr. Yakubov and all our clinical investigators for their significant contributions to the Tria LifePolymer heart valve technology development,” stated Ken Charhut, Foldax Executive Chairman.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.